Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model

Behavioural Brain Research

Volumn 268, Issue , 2014, Pages 177-184

  Ho, Shih Chun ^a,b   Hsu, Chih Chuan ^c   Pawlak, Cornelius Rainer ^d   Tikhonova, Maria A ^e   Lai, Te Jen ^a   Amstislavskaya, Tamara G ^e   Ho, Ying Jui ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Tungs' Taichung MetroHabor Hospital   (Taiwan)

^d CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^e SCIENTIFIC RESEARCH INSTITUTE OF PHYSIOLOGY AND BASIC MEDICINE   (Russian Federation)

Author keywords

Ceftriaxone; Cognition; Dementia; Glutamatergic hyperactivity; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CEFTRIAXONE; SODIUM CHLORIDE; ANTIPARKINSON AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CELL ACTIVATION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; GLUTAMATERGIC SYSTEM; HIPPOCAMPAL CA1 REGION; MALE; MEMORY DISORDER; MICROGLIA; MPTP-INDUCED PARKINSONISM; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVOUS SYSTEM; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; PATTERN RECOGNITION; PRIORITY JOURNAL; RAT; RAT MODEL; SUBSTANTIA NIGRA PARS COMPACTA; T-MAZE TEST; TREATMENT DURATION; WORKING MEMORY; ANIMAL; BRAIN; CELL DEATH; COGNITION DISORDERS; CORPUS STRIATUM; DRUG EFFECTS; MAZE TEST; PARKINSONIAN DISORDERS; PATHOLOGY; PHYSIOLOGY; PYRAMIDAL NERVE CELL; RECOGNITION; SHORT TERM MEMORY; WISTAR RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CA1 REGION, HIPPOCAMPAL; CEFTRIAXONE; CELL DEATH; COGNITION DISORDERS; CORPUS STRIATUM; MALE; MAZE LEARNING; MEMORY, SHORT-TERM; MICROGLIA; PARKINSONIAN DISORDERS; PARS COMPACTA; PYRAMIDAL CELLS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY);

EID: 84899733531     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.04.022     Document Type: Article

References (65)

1. Johnston M.V. Excitotoxicity in neonatal hypoxia. Ment Retard Dev Disabil Res Rev 2001, 7:229-234.
2. Luetjens C.M., Bui N.T., Sengpiel B., Munstermann G., Poppe M., Krohn A.J., et al. Delayed mitochondrial dysfunction in excitotoxic neuron death: cytochrome c release and a secondary increase in superoxide production. J Neurosci 2000, 20:5715-5723.
3. Perez Velazquez J.L., Frantseva M.V., Carlen P.L. In vitro ischemia promotes glutamate-mediated free radical generation and intracellular calcium accumulation in hippocampal pyramidal neurons. J Neurosci 1997, 17:9085-9094.
4. Chihab R., Oillet J., Bossenmeyer C., Daval J.L. Glutamate triggers cell death specifically in mature central neurons through a necrotic process. Mol Genet Metab 1998, 63:142-147.
5. Martin W.R. MR spectroscopy in neurodegenerative disease. Mol Imaging Biol 2007, 9:196-203.
6. Marino M.J., Valenti O., Conn P.J. Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging 2003, 20:377-397.
7. Centonze D., Gubellini P., Rossi S., Picconi B., Pisani A., Bernardi G., et al. Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism. Neuroscience 2005, 133:831-840.
8. Blandini F., Porter R.H., Greenamyre J.T. Glutamate and Parkinson's disease. Mol Neurobiol 1996, 12:73-94.
9. Cepeda C., Levine M.S. Dopamine and N-methyl-d-aspartate receptor interactions in the neostriatum. Dev Neurosci 1998, 20:1-18.
10. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., Buckman J.F. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 1999, 88:1-16.
11. Hill M.P., Ravenscroft P., Bezard E., Crossman A.R., Brotchie J.M., Michel A., et al. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther 2004, 310:386-394.
12. Loschmann P.A., De Groote C., Smith L., Wullner U., Fischer G., Kemp J.A., et al. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol 2004, 187:86-93.
13. Nash J.E., Fox S.H., Henry B., Hill M.P., Peggs D., McGuire S., et al. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2000, 165:136-142.
14. St-Pierre J.A., Bedard P.J. Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine. Eur J Pharmacol 1995, 272:123-129.
15. Kornhuber J., Weller M., Schoppmeyer K., Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994, 43:91-104.
16. Skuza G., Rogoz Z., Quack G., Danysz W. Memantine, amantadine, and l-deprenyl potentiate the action of l-dopa in monoamine-depleted rats. J Neural Transm Gen Sect 1994, 98:57-67.
17. Santini E., Muller R.U., Quirk G.J. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci 2001, 21:9009-9017.
18. Kornhuber J., Weller M. Psychotogenicity and N-methyl-d-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997, 41:135-144.
19. Nicholls D., Attwell D. The release and uptake of excitatory amino acids. Trends Pharmacol Sci 1990, 11:462-468.
20. Congeni B.L. Comparison of ceftriaxone and traditional therapy of bacterial meningitis. Antimicrob Agents Chemother 1984, 25:40-44.
21. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
22. Chu K., Lee S.T., Sinn D.I., Ko S.Y., Kim E.H., Kim J.M., et al. Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke 2007, 38:177-182.
23. Lipski J., Wan C.K., Bai J.Z., Pi R., Li D., Donnelly D. Neuroprotective potential of ceftriaxone in in vitro models of stroke. Neuroscience 2007, 146:617-629.
24. Hota S.K., Barhwal K., Ray K., Singh S.B., Ilavazhagan G. Ceftriaxone rescues hippocampal neurons from excitotoxicity and enhances memory retrieval in chronic hypobaric hypoxia. Neurobiol Learn Mem 2008, 89:522-532.
25. Brown R.G., Marsden C.D. How common is dementia in Parkinson's disease. Lancet 1984, 2:1262-1265.
26. Aarsland D., Andersen K., Larsen J.P., Lolk A., Nielsen H., Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001, 56:730-736.
27. Barnes J., Boubert L., Harris J., Lee A., David A.S. Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia 2003, 41:565-574.
28. Laatu S., Revonsuo A., Pihko L., Portin R., Rinne J.O. Visual object recognition deficits in early Parkinson's disease. Parkinsonism Relat Disord 2004, 10:227-233.
29. Ramirez-Ruiz B., Junque C., Marti M.J., Valldeoriola F., Tolosa E. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov Disord 2006, 21:1483-1487.
30. Ho Y.J., Ho S.C., Pawlak C.R., Yeh K.Y. Effects of d-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia. Behav Brain Res 2011, 219:280-290.
31. Wang A.L., Liou Y.M., Pawlak C.R., Ho Y.J. Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats. Behav Brain Res 2010, 208:38-46.
32. Wang W.F., Wu S.L., Liou Y.M., Wang A.L., Pawlak C.R., Ho Y.J. MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats. Behav Neurosci 2009, 123:1261-1270.
33. Hsieh M.H., Gu S.L., Ho S.C., Pawlak C.R., Lin C.L., Ho Y.J., et al. Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model. Behav Brain Res 2012, 229:41-47.
34. Hsieh M.H., Ho S.C., Yeh K.Y., Pawlak C.R., Chang H.M., Ho Y.J., et al. Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model. Pharmacol Biochem Behav 2012, 102:64-71.
35. Sy H.N., Wu S.L., Wang W.F., Chen C.H., Huang Y.T., Liou Y.M., et al. MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus. Pharmacol Biochem Behav 2010, 95:158-165.
36. Paxinos G.W.C. The rat brain in stereotaxic coordinates 1986, Academic Press, London.
37. Da Cunha C., Gevaerd M.S., Vital M.A., Miyoshi E., Andreatini R., Silveira R., et al. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res 2001, 124:9-18.
38. Ferro M.M., Bellissimo M.I., Anselmo-Franci J.A., Angellucci M.E., Canteras N.S., Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 2005, 148:78-87.
39. Ouyang Y.B., Voloboueva L.A., Xu L.J., Giffard R.G. Selective dysfunction of hippocampal CA1 astrocytes contributes to delayed neuronal damage after transient forebrain ischemia. J Neurosci 2007, 27:4253-4260.
40. Albin R.L., Greenamyre J.T. Alternative excitotoxic hypotheses. Neurology 1992, 42:733-738.
41. Gevaerd M.S., Takahashi R.N., Silveira R., Da Cunha C. Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats. Brain Res Bull 2001, 55:101-106.
42. Braga R., Kouzmine I., Canteras N.S., Da Cunha C. Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats. Exp Neurol 2005, 192:134-141.
43. Bellissimo M.I., Kouzmine I., Ferro M.M., de Oliveira B.H., Canteras N.S., Da Cunha C. Is the unilateral lesion of the left substantia nigra pars compacta sufficient to induce working memory impairment in rats. Neurobiol Learn Mem 2004, 82:150-158.
44. Ferro M.M., Angelucci M.E., Anselmo-Franci J.A., Canteras N.S., Da Cunha C. Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease. Braz J Med Biol Res 2007, 40:89-96.
45. Graham W.C., Robertson R.G., Sambrook M.A., Crossman A.R. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci 1990, 47:PL91-PL97.
46. Goetz C.G. New lessons from old drugs: amantadine and Parkinson's disease. Neurology 1998, 50:1211-1212.
47. Turski L., Bressler K., Rettig K.J., Loschmann P.A., Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-d-aspartate antagonists. Nature 1991, 349:414-418.
48. Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F., Corsini G.U. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J Neurochem 1992, 59:733-739.
49. Pittenger C., Krystal J.H., Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006, 3:69-81.
50. Mao J. Glutamate transporter: an unexpected target for some antibiotics. Mol Pain 2005, 1:5.
51. Beart P.M., O'Shea R.D. Transporters for l-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol 2007, 150:5-17.
52. Rothstein J.D., Dykes-Hoberg M., Pardo C.A., Bristol L.A., Jin L., Kuncl R.W., et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 16:675-686.
53. Kanai Y., Hediger M.A. The glutamate and neutral amino acid transporter family: physiological and pharmacological implications. Eur J Pharmacol 2003, 479:237-247.
54. Huang S.S., He J., Zhao D.M., Xu X.Y., Tan H.P., Li H. Effects of mutant huntingtin on mGluR5-mediated dual signaling pathways: implications for therapeutic interventions. Cell Mol Neurobiol 2010, 30:1107-1115.
55. Perry V.H., Cunningham C., Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007, 7:161-167.
56. Ebert S., Goos M., Rollwagen L., Baake D., Zech W.D., Esselmann H., et al. Recurrent systemic infections with Streptococcus pneumoniae do not aggravate the course of experimental neurodegenerative diseases. J Neurosci Res 2010, 88:1124-1136.
57. Nau R., Prange H.W., Muth P., Mahr G., Menck S., Kolenda H., et al. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother 1993, 37:1518-1524.
58. Verma R., Mishra V., Sasmal D., Raghubir R. Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury. Eur J Pharmacol 2010, 638:65-71.
59. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
60. Yasuda Y., Shimoda T., Uno K., Tateishi N., Furuya S., Yagi K., et al. The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J Neuroimmunol 2008, 204:43-51.
61. Nakajima K., Kohsaka S. Microglia: neuroprotective and neurotrophic cells in the central nervous system. Curr Drug Targets Cardiovasc Haematol Disord 2004, 4:65-84.
62. McGeer P.L., McGeer E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004, 10(Suppl 1):S3-S7.
63. Roelcke U., Barnett W., Wilder-Smith E., Sigmund D., Hacke W. Untreated neuroborreliosis: Bannwarth's syndrome evolving into acute schizophrenia-like psychosis. A case report. J Neurol 1992, 239:129-131.
64. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2007, 22:659-661.
65. Miller B.R., Dorner J.L., Shou M., Sari Y., Barton S.J., Sengelaub D.R., et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 2008, 153:329-337.